Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin with Bendamustine and Rituximab in CD30+ Relapsed/Refractory B-Cell NHL
NCT02623920Phase 2Withdrawn
- Sponsor
- University of Arizona
- Start
- Dec 2015
- Primary completion
- May 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in B-cell non-Hodgkin lymphoma, sponsored by University of Arizona. Primary endpoints: Complete Response Rate at 2 years and Overall Response Rate at 2 years. Planned start Dec 2015; status: withdrawn.
02
Drugs
brentuximab vedotin
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT02623920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02623920.